| Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).Gastric Cancer | PMID 39499377无 PMCID | 2025-Jan | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.Headache | PMID 39501727PMC11726011 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.Bone Marrow Transplant | PMID 39506073PMC11726446 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.Radiother Oncol | PMID 39522824无 PMCID | 2025-Jan | 0.90 | The record describes a Phase III randomized trial in human oncology (head and neck cancer) with a time-to-event primary endpoint (locoregional control). However, the abstract focuses on quality assurance and protocol adherence analysis of the radiotherapy intervention, not on the formal efficacy results of a drug-containing intervention. No drug intervention is mentioned; the trial investigates scheduled adaptive radiotherapy and dose painting. While the primary endpoint is time-to-event, the abstract does not report Kaplan-Meier curves, hazard ratios, or other time-to-event efficacy results; it reports on the impact of protocol deviations. Therefore, it does not meet the criteria for inclusion in a KM digitization cohort requiring a drug intervention and formal time-to-event efficacy results. | 待处理 |
| Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39522825无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39531903无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.Adv Ther | PMID 39535685PMC11782330 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.Am J Clin Dermatol | PMID 39546129PMC11742460 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis.Clin Immunol | PMID 39561927PMC11631659 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.Lancet Diabetes Endocrinol | PMID 39586309无 PMCID | 2025-Jan | 0.85 | The study is an oncology phase 3 randomized trial with original results, but it is excluded because the intervention is radioiodine (a radioisotope, not a drug) and the primary endpoint is not a standard time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. | 待处理 |
| Efficacy and Safety of a Dedicated Device for Cerebral Venous Thrombectomy: A Pilot Randomized Clinical Trial.Stroke | PMID 39601121无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.Lancet Oncol | PMID 39612919无 PMCID | 2025-Jan | 0.95 | The study is a Phase III randomized trial in oncology with drug interventions and reports final results for its primary endpoint. However, the primary endpoint is pathological complete response (pCR), which is a binary efficacy measure, not a time-to-event endpoint such as overall survival or progression-free survival. Therefore, it does not meet the core criterion of having a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.Lung Cancer | PMID 39615412无 PMCID | 2025-Jan | 0.90 | The record describes a randomized Phase III trial comparing two radiation techniques (PCI vs. HA-PCI) for a time-to-event endpoint (brain metastases). While it meets criteria for oncology, human, randomized, phase, and time-to-event, it fails the mandatory drug intervention criterion, as the intervention is purely a non-drug radiotherapy technique. | 待处理 |
| Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.Lancet Neurol | PMID 39617030无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia.Curr Med Res Opin | PMID 39618256无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).Curr Med Res Opin | PMID 39625230无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39642900无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Lancet Haematol | PMID 39644907无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39657575无 PMCID | 2025-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.Lancet Oncol | PMID 39675376无 PMCID | 2025-Jan | 0.95 | The report is a phase 3 randomized trial in oncology with a drug intervention, but the presented results focus on a quality-of-life endpoint (GHS) at 24 months. The time-to-event efficacy endpoint (ipsilateral breast tumour recurrence) is a co-primary endpoint but is explicitly noted as 'not reported here'. Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).J Alzheimers Dis | PMID 39686620无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.Mult Scler | PMID 39690897无 PMCID | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39700681无 PMCID | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis.Mult Scler Relat Disord | PMID 39733600无 PMCID | 2025-Jan | 0.80 | The study is a secondary analysis/prognostic model development using data from two Phase II/III RCTs of fingolimod in Multiple Sclerosis. While it involves a drug, randomized trials, and time-to-event analysis (Cox models for relapse), it is not an oncology study. Furthermore, it is not the primary formal report of the original trial results but rather a subsequent analysis aiming to predict individual treatment response. Therefore, it does not meet the core criteria for inclusion in an oncology Kaplan-Meier digitization cohort. | 待处理 |
| Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis.Cancer Med | PMID 39737542PMC11686335 | 2025-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.Clin Transplant疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图。 | PMID 39739990PMC11683858 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.ESMO Open | PMID 39754976PMC11758124 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.Lancet Haematol | PMID 39756844PMC12321245 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.Eur J Neurol | PMID 39790009PMC11718218 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.J Prev Alzheimers Dis | PMID 39800452PMC12184016 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial.J Clin Hypertens (Greenwich) | PMID 39821945PMC11771783 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.Ann Hematol | PMID 39841198PMC11868214 | 2025-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.JCO Precis Oncol | PMID 39854658PMC11835511 | 2025-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.JCO Precis Oncol | PMID 39854659PMC11781561 | 2025-Jan | 0.85 | The record describes a prescreening prevalence study of FGFR2b overexpression for a Phase III trial. While it is linked to a definitive randomized controlled oncology trial, it does not report the required survival or efficacy outcomes (e.g., OS, PFS, ORR, death, hazard ratios). It is a secondary/biomarker analysis report focused on prevalence, not trial efficacy. | 待处理 |
| Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol | PMID 39889245无 PMCID | 2025-Jan | 0.95 | This is a post-hoc subgroup/biomarker analysis (digital pathology-based AI) of the primary SPARTAN trial. While it reports time-to-event outcomes for a drug-containing arm, it is not the original primary efficacy report of the randomized trial, but an exploratory biomarker study within it. | 待处理 |
| Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Acta Haematol | PMID 38599195PMC11809454 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial.Acta Haematol | PMID 38615657PMC11723503 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Cerebral Oximetry-Guided Treatment on Brain Injury in Preterm Infants as Assessed by Magnetic Resonance Imaging at Term Equivalent Age: An Ancillary SafeBoosC-III Study.Neonatology | PMID 38934161无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR).Pract Radiat Oncol | PMID 39233006无 PMCID | 2025 | 0.85 | While the underlying trial is a Phase III randomized oncology trial, this specific publication is a quality assurance report for the SBRT component. It does not present primary or secondary efficacy results based on a time-to-event endpoint (OS, PFS, etc.). Furthermore, the intervention reported here (SBRT) is non-drug. | 待处理 |
| Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.Digestion | PMID 39317165PMC12129419 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis.Int Arch Allergy Immunol | PMID 39647474PMC12169803 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.Dig Dis | PMID 39701047PMC11965839 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.Asia Pac J Ophthalmol (Phila) | PMID 39818248无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.Chron Respir Dis | PMID 39854278PMC11760128 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.Expert Rev Gastroenterol Hepatol | PMID 39909733无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of GutGard® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial.Complement Med Res | PMID 39929150PMC11892464 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial.Curr Neuropharmacol | PMID 40016875PMC12163466 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of honey-ginger mouthwash on oral mucositis in patients undergoing chemotherapy.J Immunoassay Immunochem | PMID 40134126无 PMCID | 2025 | 0.95 | The study fails two key eligibility criteria for the specified cohort: (1) the intervention is not a systemic anticancer drug, and (2) the primary endpoint is not a time-to-event efficacy endpoint. While it is an oncology RCT with human subjects, a Phase III label, and reports primary results, it does not meet the core requirements for inclusion in a Kaplan-Meier digitization cohort focused on drug interventions and survival/time-to-event outcomes. | 待处理 |
| Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials.Dermatology | PMID 40209685PMC12143848 | 2025 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.Oncol Res Treat | PMID 40418924PMC12237281 | 2025 | 0.95 | The study is an oncology randomized Phase III trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier/HR). The primary endpoint is patient-reported treatment satisfaction, and secondary endpoints include recurrent VTE and mortality, but the reported results are based on scale scores and proportions, not time-to-event analysis. | 待处理 |